These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 3126593

  • 21. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A, Bock PR.
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [Abstract] [Full Text] [Related]

  • 22. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H.
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [Abstract] [Full Text] [Related]

  • 23. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H.
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [Abstract] [Full Text] [Related]

  • 24. Maintenance therapy for superficial bladder cancer.
    Baselli EC, Greenberg RE.
    Oncology (Williston Park); 2001 Jan; 15(1):85-8; discussion 88-91. PubMed ID: 11271984
    [Abstract] [Full Text] [Related]

  • 25. Overview of treatment of superficial bladder cancer.
    Soloway MS.
    Urology; 1985 Oct; 26(4 Suppl):18-26. PubMed ID: 4049626
    [Abstract] [Full Text] [Related]

  • 26. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance.
    Griffiths TR, Charlton M, Neal DE, Powell PH.
    J Urol; 2002 Jun; 167(6):2408-12. PubMed ID: 11992047
    [Abstract] [Full Text] [Related]

  • 27. Selecting initial therapy for bladder cancer.
    Soloway MS.
    Cancer; 1987 Aug 01; 60(3 Suppl):502-13. PubMed ID: 3109725
    [Abstract] [Full Text] [Related]

  • 28. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun 01; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 29. Effects of intravesical chemotherapy and immunotherapy on semen analysis.
    Raviv G, Pinthus JH, Shefi S, Mor Y, Kaufman-Francis K, Levron J, Weissenberg R, Ramon J, Madgar I.
    Urology; 2005 Apr 01; 65(4):765-7. PubMed ID: 15833524
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Management of superficial bladder cancer in a community setting.
    Haas JA.
    Urology; 1985 Oct 01; 26(4 Suppl):51-4. PubMed ID: 3931328
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Long term follow-up of intravesical Bacillus Calmette-Guerin for the treatment of bladder transitional cell carcinoma.
    Leblanc B, Duclos AJ, Bénard F, Valiquette L, Paquin JM, Lapointe S, Mauffette F, Pharand D, Faucher R, Drouin G, Perreault JP.
    Can J Urol; 2000 Feb 01; 7(1):944-8. PubMed ID: 11121250
    [Abstract] [Full Text] [Related]

  • 34. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
    Rintala E, Jauhiainen K, Alfthan O.
    Prog Clin Biol Res; 1989 Feb 01; 310():271-4. PubMed ID: 2505270
    [No Abstract] [Full Text] [Related]

  • 35. Is there an optimal treatment scheme for adjuvant intravesical therapy? Preliminary analysis of an EORTC protocol comparing early and delayed instillation with and without maintenance of either adriamycin or mitomycin-C in patients with superficial transitional carcinoma of the bladder.
    Kurth KH, Bouffioux C, Sylvester R, de Pauw M.
    Prog Clin Biol Res; 1988 Feb 01; 269():525-37. PubMed ID: 3134663
    [No Abstract] [Full Text] [Related]

  • 36. Current concepts in the management of superficial bladder cancer.
    Soloway MS.
    Arch Esp Urol; 1990 Feb 01; 43 Suppl 2():115-21. PubMed ID: 2129003
    [No Abstract] [Full Text] [Related]

  • 37. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients.
    Orsola A, Trias I, Raventós CX, Español I, Cecchini L, Búcar S, Salinas D, Orsola I.
    Eur Urol; 2005 Aug 01; 48(2):231-8; discussion 238. PubMed ID: 15963635
    [Abstract] [Full Text] [Related]

  • 38. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
    Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, Okuyama A, Nonomura N.
    J Urol; 2009 Apr 01; 181(4):1894-900. PubMed ID: 19237175
    [Abstract] [Full Text] [Related]

  • 39. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
    Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, Shinohara N, Shinka T, Tachibana M, Naito S, Hirao Y, BCG Tokyo 172 Strain Study Group.
    Urology; 2006 Mar 01; 67(3):545-9. PubMed ID: 16527576
    [Abstract] [Full Text] [Related]

  • 40. Adjuvant intravesical therapy for superficial bladder cancer.
    Batts CN.
    Ann Pharmacother; 1992 Oct 01; 26(10):1270-6. PubMed ID: 1421654
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.